drugset / Trial / NCT00759460

Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia

NCT00759460

Phase 3 Completed 250 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this exploratory study is to evaluate the effects of sertindole and olanzapine on metabolic parameters and syndrome in patients with schizophrenia.

Timeline

Start
2007-03
Primary completion
2008-03
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Olanzapine Small molecule 10 mg Oral
Comparator Olanzapine Small molecule 20 mg Oral
Subject Sertindole Small molecule 12 mg Oral
Subject Sertindole Small molecule 20 mg Oral

Indications